ZTS (Zoetis Inc.) צמיחה צפויה ברווח נקי למניה השנה

High regulatory barriers and patent protection securely shield the Zoetis Inc. (ZTS) business from new entrants. Dominance in this niche allows for the effective scaling of sales while keeping operating expenses under control. Revenues are based on the sale of veterinary vaccines and medications for livestock and pets. Annual EPS progress reflects market sentiment, where -1.60 serves as the base value of the parameter.

The stability of the workforce at Zoetis Inc. (ZTS), underpinned by the high qualifications of its veterinarians and the attractiveness of the sector, is directly reflected in the YoY net income per share dynamics. This indicator measures the annual EPS growth rate by calculating the difference between the current and previous periods, allowing investors to assess the real efficiency of business scaling and its resilience to market shocks.